GET DAILY SIGNALSWhy Is Grail, Inc. (GRAL) Stock Down 6.06% Today?
Key Takeaways
- Down 6.06% — shares of GRAL fell to roughly $118.03, down from the prior session's close of $125.64.
- Primary driver: a technical pullback and profit-taking after a steep multi-month rally, as the stock retreats from recent highs near $159.
- Secondary overhang: lingering disappointment from the early-November Q3 earnings miss, a lowered full-year growth outlook, and ongoing securities litigation tied to the NHS-Galleri trial.
- Market context: high-beta healthcare and growth names face renewed selling pressure as momentum cools and short-term technical indicators turn bearish.
- What's next: traders are watching the anticipated FDA decision on the Galleri test (expected early Q1 2027), reimbursement developments, and the company's next earnings report.
- For more detail on this stock's valuation and outlook, explore our Price Targets, Earnings, and Forecast pages.
- To see which strategies are performing best in the current market, explore Trending AI Robots.
Opening Summary
GRAL, also known as Grail, Inc., is a healthcare company focused on early cancer detection. Its flagship product, the Galleri test, is a blood-based multi-cancer early detection (MCED) screening tool designed to identify multiple cancer types before symptoms appear. The company was spun off from Illumina in 2024 and has since become one of the most closely watched names in the diagnostics space.
In today's trading session, the stock fell approximately 6.06%, dropping to about $118.03 from a prior close of $125.64. The decline extends a broader pullback that has seen the shares give back a substantial portion of their recent gains, with the stock now trading well below its 52-week high of $166.48. Markets attributed the move primarily to technical selling and profit-taking rather than a single new fundamental announcement.
Technical Breakdown and Profit-Taking
The most immediate catalyst behind today's decline appears to be technical. GRAL has been one of the market's strongest performers over the past several months, rallying more than 80% over the trailing three-month period and more than 45% year to date. After such an extended run, momentum indicators had become stretched, and the shares have now entered a corrective phase.
Momentum gauges such as the stochastic oscillator and MACD have turned decisively lower in recent sessions, signaling that short-term buying pressure has faded. The stock has broken back below several key intermediate moving averages, converting what had been support into near-term resistance. With a beta well above 2, the shares carry outsized volatility, amplifying both upswings and downswings relative to the broader market.
Post-Earnings Disappointment Lingers
Today's slide also reflects the market continuing to digest Grail's third-quarter 2026 results, reported in early November. The company posted revenue of roughly $37.5 million, missing analyst expectations by a wide margin, while its net loss widened on a year-over-year basis. Management also lowered full-year Galleri revenue growth guidance to a range of 17%–21%, reflecting softer growth and a pricing-promotion strategy that reduced average selling prices to prioritize volume.
Although a favorable FDA advisory committee vote on Galleri has kept the long-term regulatory story intact, the revenue miss and margin pressure have left investors reassessing near-term valuations after the stock's rapid appreciation. That repricing has continued to weigh on the shares in the sessions following the report.
Legal and Regulatory Overhang
A further source of uncertainty is the securities litigation tied to the NHS-Galleri trial. Following the February 2026 disclosure that the trial did not meet its primary endpoint, multiple law firms filed class-action suits alleging the company misled investors about the study's design and prospects. Periodic investor notices and case-related headlines have kept the legal overhang in view, adding to the cautious tone around the shares even as the company emphasizes positive secondary findings, including a reduction in Stage IV diagnoses and higher detection of early-stage deadly cancers.
Market Context and Trading Activity
The decline is occurring against a backdrop of cooling risk appetite in high-multiple, high-beta healthcare and biotechnology names. While broader indices have not moved in lockstep with Grail, speculative growth stocks that enjoyed sharp rallies earlier in the year have been more vulnerable to profit-taking as investors rotate toward more defensive positioning.
The stock's elevated beta and its distance from prior support levels have made it a focal point for short-term traders. With the shares now well below recent peaks, technicians are watching whether buying emerges near the psychologically important $115–$120 zone or whether the corrective move extends further toward lower support.
What Comes Next for GRAL
Looking ahead, the dominant catalyst remains the U.S. Food and Drug Administration's decision on the Galleri premarket approval application, which management expects in early Q1 2027. An approval would be the gateway to broader coverage and reimbursement, including potential engagement with Medicare and commercial payers.
Nearer term, investors will monitor the company's next quarterly earnings release, updates on international expansion through the Samsung partnership, and any progress on reimbursement discussions. Risks include continued margin compression from promotional pricing, the resumption of the Illumina royalty obligation in late December, intensifying competition in the multi-cancer early detection market, and the unresolved securities litigation. The combination of a still-developing regulatory pathway and a high-beta share price suggests volatility is likely to persist.
Trending AI Robots
Tickeron offers hundreds of AI trading bots that cover thousands of tickers, but only the strongest performers under current market conditions are featured in the curated Trending AI Robots section. These bots vary by strategy, timeframe, performance metrics, and the symbols they trade, giving investors a range of approaches to explore. To see which automated strategies are currently leading the market, visit the Trending AI Robots page.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
GRAL's Stochastic Oscillator sits in oversold zone for 3 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +7.51% 3-day Advance, the price is estimated to grow further. Considering data from situations where GRAL advanced for three days, in 116 of 133 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
Bearish Trend Analysis
The 10-day RSI Indicator for GRAL moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 similar instances where the indicator moved out of overbought territory. In 22 of the 22 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GRAL as a result. In 34 of 43 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 79%.
The Moving Average Convergence Divergence Histogram (MACD) for GRAL turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 20 similar instances when the indicator turned negative. In 16 of the 20 cases the stock turned lower in the days that followed. This puts the odds of success at 80%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GRAL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.
GRAL broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for GRAL entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. GRAL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 43 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.133) is normal, around the industry mean (67.298). P/E Ratio (-12.533) is within average values for comparable stocks, (4.239). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (18.248) is also within normal values, averaging (9.775).
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GRAL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalSpecialties
Advertisement